CXCL9 recombinant adeno-associated virus (AAV) virotherapy sensitizes glioblastoma (GBM) to anti-PD-1 immune checkpoint blockade.
von Roemeling C, Yegorov O, Yang C, Klippel K, Russell R, Trivedi V, Bhatia A, Doonan B, Carpenter S, Ryu D, Grippen A, Futch H, Ran Y, Hoang-Minh L, Weidert F, Golde T, Mitchell D.
von Roemeling C, et al. Among authors: klippel k.
Res Sq [Preprint]. 2023 Nov 14:rs.3.rs-3463730. doi: 10.21203/rs.3.rs-3463730/v1.
Res Sq. 2023.
PMID: 38014191
Free PMC article.
Preprint.